Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02155621 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Personalized Oncogenomics (POG) Program of British Columbia

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 22, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Dec 2025 to Mar 2026v6
  2. Primary completion date: Oct 2020 to Dec 2025 Completion date: Jun 2025 to Dec 2025 · Eligibility criteria shortened, about 19 words · Study description expanded, about 204 words · 1 morev5 Show 4 more changesShow less
    • Completion date: Jun 2025 to Dec 2025
    • Eligibility criteria shortened, about 19 words
    • Study description expanded, about 204 words
    • Publications: 10 to 12

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date: Jun 2020 to Oct 2020v4
  4. Eligibility criteria expanded, about 16 wordsv3 See this version in full on ClinicalTrials.gov ↗
  5. Trial status: Not Yet Recruiting to Recruiting Start date: Jun 2014 to Jul 2014 · Site details revisedv2 Show 2 more changesShow less
    • Start date: Jun 2014 to Jul 2014
    • Site details revised
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The genomic heterogeneity of cancers implies that to effectively use targeted therapies the investigators will need to assess each individual cancer and match it to a biologically relevant targeted therapy. The investigators will use full genome sequencing to try to identify cancer "drivers" and corresponding drugs that may inhibit these pathways.
Trial Details
NCT Number NCT02155621
Lead Sponsor British Columbia Cancer Agency
Collaborators: BC Cancer Foundation
Conditions Metastatic Cancers, Advanced Cancers, Cancers That Cannot be Treated With Curative Intent
Enrollment 5,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov